SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-327250"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-327250" > An Intraprostatic M...

  • Tammela, T LTampere Univ Hosp, Dept Urol, Tampere, Finland.; Univ Tampere, Tampere, Finland,Department of Urology, Tampere University Hospital and University of Tampere, Tampere, Finland (författare)

An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer

  • Artikel/kapitelEngelska2017

Förlag, utgivningsår, omfång ...

  • Ovid Technologies (Wolters Kluwer Health),2017
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-327250
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-327250URI
  • https://doi.org/10.1016/j.juro.2017.07.072DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-63426URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • PURPOSE: To investigate tolerability, safety and antitumor effects of a novel intra-prostatic depot formulation of antiandrogen 2-hydroxyflutamide (2-HOF in NanoZolid(®)) in men with localized prostate cancer (PCa).MATERIALS AND METHODS: Two clinical trials, LPC-002 and LPC-003, were conducted on a total of 47 men. The formulation was injected transrectally into the prostate with ultrasound guidance. In LPC-002 the effects on prostate specific antigen (PSA) and prostate volume (PV) were measured over 6 months on 24 patients. In LPC-003, antitumor effects were evaluated with histopathology, magnetic resonance imaging (MRI) including spectroscopy (MRS) during 6 or 8 weeks on 23 patients. In both studies, testosterone and 2-HOF in plasma were measured, as well as quality-of-life parameters.RESULTS: In LPC-002 (mean dose 690 mg) a reduction in PSA and PV was observed. The nadir values for PSA and PV were on average 24.9 % and 14.0 % below baseline, respectively. When increasing the dose in LPC-003 (920 mg and 1740 mg), the average PSA dropped 16 % and 23 %, respectively, after 6 and 8 weeks. MRI/MRS showed morphological changes and a global drop in metabolite concentrations following treatment indicating an antitumor response. The injections did not result in hormone related side effects. In total, three serious adverse events were reported, all resolved by oral antibiotic treatment.CONCLUSIONS: The intraprostatic injections of 2-HOF depot formulations indicated anti-tumor effects and proved safe and tolerable. However, for better anti-cancer effects higher doses and better dose distribution are suggested.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Häggman, MichaelUppsala universitet,Urologkirurgi,Department of Urology, Uppsala University Hospital, Uppsala, Sweden(Swepub:uu)michhagg (författare)
  • Ladjevardi, SamUppsala universitet,Urologkirurgi,Department of Urology, Uppsala University Hospital, Uppsala, Sweden(Swepub:uu)salad626 (författare)
  • Taari, KHelsinki Univ Hosp, Helsinki, Finland,Department of Urology, Helsinki University Hospital, Helsinki, Finland (författare)
  • Isotalo, TPaijiat Hame Cent Hosp, Lahti, Finland,Department of Urology, Päijät-Häme Central Hospital, Lahti, Finland (författare)
  • Lennernäs, HansUppsala universitet,Institutionen för farmaci,Department of Pharmacy, Uppsala University, Uppsala, Sweden(Swepub:uu)hanslenn (författare)
  • Weis, Jan,1956-Uppsala universitet,Radiologi,Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden(Swepub:uu)janweis (författare)
  • von Below, Catrin,1970-Uppsala universitet,Radiologi,Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden(Swepub:uu)cavon168 (författare)
  • Wassberg, CeciliaUppsala universitet,Radiologi,Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden(Swepub:uu)ceciwass (författare)
  • Lennernäs, Bo,1963-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology, Örebro University Hospital, Örebro, Sweden,Univ Orebro, Dept Oncol, Orebro, Sweden(Swepub:oru)bols (författare)
  • Tolf, AnnaUppsala universitet,Klinisk och experimentell patologi,Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden(Swepub:uu)annto745 (författare)
  • Axén, NLIDDS AB, Uppsala, Sweden (författare)
  • Gölander, C-GLIDDS AB, Uppsala, Sweden (författare)
  • Ahlström, Håkan,1953-Uppsala universitet,Radiologi,Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden(Swepub:uu)hakanahl (författare)
  • Tampere Univ Hosp, Dept Urol, Tampere, Finland.; Univ Tampere, Tampere, FinlandDepartment of Urology, Tampere University Hospital and University of Tampere, Tampere, Finland (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Urology: Ovid Technologies (Wolters Kluwer Health)198:6, s. 1333-13390022-53471527-3792

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy